

**ANNUAL UROLOGIC ONCOLOGY
VISITING PROFESSORS**

OCTOBER 20-21, 2010

PETER R. CARROLL MD
UNIVERSITY OF CALIFORNIA,
SAN FRANCISCO, CA

SEPTEMBER 30 -
OCTOBER 1, 2009

JOEL NELSON MD
UNIVERSITY OF PITTSBURGH
SCHOOL OF MEDICINE,
PITTSBURGH, PA

OCTOBER 29-30, 2008

MARK P. SCHOENBERG MD
BRADY UROLOGICAL INSTITUTE
JOHNS HOPKINS HOSPITAL
BALTIMORE, MD

SEPTEMBER 25-26, 2007

JUDD MOUL MD
DUKE UNIVERSITY MEDICAL CENTER
DUKE PROSTATE CENTER

OCTOBER 11-12, 2006

PETER SCARDINO MD
MEMORIAL SLOAN KETTERING
CANCER CENTER
NEW YORK, NY

OCTOBER 5-6, 2005

COLIN DINNEY MD
UNIVERSITY OF TEXAS
M.D. ANDERSON CANCER CENTRE

7TH ANNUAL UROLOGIC ONCOLOGY
VISITING PROFESSOR
OCTOBER 5-6, 2011



MARTIN GLEAVE MD FRCS FACS

DISTINGUISHED PROFESSOR AND VICE-CHAIR,
DEPARTMENT OF UROLOGIC SCIENCES
UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER

LIBER ERO BRITISH COLUMBIA LEADERSHIP CHAIR
IN PROSTATE RESEARCH

DIRECTOR, THE VANCOUVER PROSTATE CENTRE
DIRECTOR OF RESEARCH, DEPT. OF UROLOGIC SCIENCES



MARTIN GLEAVE MD FRCSC FACS

DEPARTMENT OF UROLOGIC
SCIENCES, UNIVERSITY OF BRITISH
COLUMBIA, VANCOUVER

Dr. Gleave is a Distinguished Professor in the Department of Urologic Sciences at the University of British Columbia, Director of the Vancouver Prostate Center, and Director of Research for the Department of Urologic Sciences at UBC. He is the past Chair of the National Cancer Institute of Canada GU Clinical Trials Group, and the Canadian Uro-Oncology Group. He has published > 275 peer-reviewed papers and has > \$50M in peer reviewed research funding. Dr. Gleave's research focus involves the study of molecular mechanisms mediating progression of prostate cancer to its lethal stage of castrate resistance, and use of this information to develop integrated multimodality therapies. His research team employs high-throughput approaches to target discovery, validation, credentialization, and therapeutic development. He has characterized the role of many genes in cancer progression, leading to several patented targeted inhibitors and first-in-man trials of new anti-cancer drugs. Dr. Gleave established a role for clusterin as a cancer-related cell survival protein involved treatment resistance and developed an inhibitor, OGX-011, that improved efficacy of hormone- and chemotherapies in prostate and other cancer models. 7 clinical studies across North America have been completed, including a randomized trial demonstrating a 7 month gain in overall survival when OGX-011 was combined with docetaxel. Two Phase III registration trials with OGX-011 began in 2010. Additional targeted agents have been developed against IGFBP2, IGFBP-5, and Hsp27 in various stages of preclinical and early clinical development. Intellectual property from these targets has been licensed from UBC to OncoGenex Technologies, a Nasdaq-listed biotechnology company founded by Dr. Gleave. Dr. Gleave is the Chief Scientific Officer at OncoGenex, while retaining his Professorship and laboratory at UBC.

Dr. Gleave is the recipient of numerous awards, including the NCIC's prestigious William Rawls Award for contributions to cancer control in Canada, the Society of Urologic Oncology's Young Investigator Award, Finalist, Ernst and Young Entrepreneur of the Year, 2004, and Clinician-Scientist Award, Prostate Cancer Foundation. In 2003, he was appointed a Distinguished University Scholar at the University of British Columbia, and a BC Leadership Chair through the Province of BC's Leading Edge Endowment Fund in 2005. Dr. Gleave was awarded the 2006 BC Biotech Award for Innovation and Achievement, and the 2007 BC Innovation Council Frontiers in Research Award.

7TH ANNUAL UROLOGIC ONCOLOGY VISITING PROFESSOR **PROGRAM**

WEDNESDAY, OCTOBER 5TH, 2011

ROYAL VICTORIA HOSPITAL

2:00 – 4:00 pm PRESENTATIONS BY UROLOGY
RESIDENTS
ROOM: S6.84

MONTREAL NEUROLOGICAL INSTITUTE

5:00 – 6:30 pm UROLOGY GRAND ROUNDS LECTURE
“**TARGETING THE MOLECULAR BASIS
OF CASTRATE RESISTANT PROSTATE
CANCER**”
JEANNE TIMMINS AMPHITHEATRE
WEBSTER PAVILION, 1ST FLOOR

THURSDAY, OCTOBER 6TH, 2011

MONTREAL GENERAL HOSPITAL

7:30 – 8:30 am SURGICAL GRAND ROUNDS
“**HORMONAL THERAPY FOR
PROSTATE CANCER:
BEYOND SIMPLE CASTRATION**”
OSLER AMPHITHEATRE, A6.105